Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology
Open single-cell discovery grant for oncology and immunology up to 100K Euro aimed at addressing unmet clinical needs.
Immunological diseases and Cancer are complex disorders and pose an enormous clinical burden due to diagnosis, stratification, and treatment challenges. Single-cell technologies are powerful in analysing the cellular landscape within complex diseases and are increasingly popular as a tool in identifying rare cells underlying the etiology of disease onset and progression in these areas. We are opening a single-cell discovery grant for oncology and immunology.
Scailyte is a recognized leader in combining single-cell analysis with artificial intelligence (AI) based data analytics. Our best-in-class algorithm associates patterns in single-cell data with disease status and further integrates multiple clinical parameters for a sensitive and impactful discovery.
We offer a co-finance partnership sharing 50% of costs (up to 100K Euro) for single-cell data acquisition including scRNA sequencing and CyTOF analysis, and subsequent artificial intelligence (AI)-based high-end bioinformatics services for translational oncology and immunology projects. The expected outcome of these grants should be addressing unmet medical needs and targets the discovery of clinically relevant biosignatures from single-cell data for diagnostic and prognostic pharmaceutical use. A maximum of three projects will be selected for this award through a formal selection process and notified within one month of the deadline.
Application:
Link to the brief application form: Click Here
Deadline: 30th September 2021
Recent News
Recent News
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Recent News
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Recent News
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Recent News
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...
Recent News
ISCT 2023
Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...